Biotech News
Related news
SYBXSynlogic2026-07-29 11:00 EST
Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement
ALTAltimmune2026-04-23 03:25 EST
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
SGMTSagimet Biosciences2026-04-27 11:15 EST
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
MNKDMannKind2026-07-28 20:01 EST
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MNKDMannKind2026-07-24 10:30 EST
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
SENSSenseonics2026-05-01 01:50 EST
Senseonics Announces Pricing of $80 Million Public Offering of Common Stock and Pre-Funded Warrants
SENSSenseonics2026-05-04 20:01 EST
Senseonics Announces Closing of $92 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
ALTAltimmune2026-04-27 11:00 EST
Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities
MLYSMineralys Therapeutics2026-06-03 10:05 EST
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-08-05 20:01 EST
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-07-29 10:30 EST
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF
MNKDMannKind2026-07-28 20:01 EST
MannKind to Report Second Quarter Financial Results and Host Conference Call on August 5, 2026
MNKDMannKind2026-07-24 10:35 EST
MannKind Announces $50 Million Private Placement
MNKDMannKind2026-07-24 10:30 EST
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease
Stock data
- Close
- 3.89 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States